CORT – corcept therapeutics incorporated (US:NASDAQ)
Stock Stats
News
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORT
Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant) [Yahoo! Finance]
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Corcept Therapeutics (CORT) had its price target raised by Canaccord Genuity Group Inc. from $100.00 to $110.00. They now have a "buy" rating on the stock.
Form SCHEDULE 13G/A CORCEPT THERAPEUTICS Filed by: VANGUARD GROUP INC
Form 144 CORCEPT THERAPEUTICS Filed by: BELANOFF JOSEPH K
Form 8-K CORCEPT THERAPEUTICS For: Mar 25
Form 4 CORCEPT THERAPEUTICS For: Mar 20 Filed by: WILSON JAMES N
Form 4 CORCEPT THERAPEUTICS For: Mar 20 Filed by: Guyer William
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.